Compare stocks

CLLS vs GNTA

Cellectis S.A. American Depositary Shares and Genenta Science S.p.A. American Depositary Shares

Compare the businesses

Cellectis S.A. American Depositary Shares

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.

Open CLLS dashboard ↗

Genenta Science S.p.A. American Depositary Shares

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Open GNTA dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗